BAM
PACB icon

Byrne Asset Management’s Pacific Biosciences PACB Stock Holding History

Byrne Asset Management’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-14,000
Closed -$19K – 558
2024
Q2 		$19K Buy
14,000
+10,800
+338% +$21.8K 0.01% 299
2024
Q1 		$12K Buy
+3,200
New +$18.7K 0.01% 342
2022
Q4 		– Sell
-5,140
Closed -$30K – 550
2022
Q3 		$30K Buy
5,140
+1,840
+56% +$10.6K 0.02% 248
2022
Q2 		$15K Buy
+3,300
New +$20.1K 0.01% 318

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Byrne Asset Management's PACB Position: Q3 2024 in Review

Byrne Asset Management sold out of Pacific Biosciences (PACB) in Q3 2024, closing a stake of 14,000 shares — an estimated $19K sold.

Byrne Asset Management first reported a position in PACB in Q2 2022 and held it in 4 quarters. The position peaked at $30K in Q3 2022. 226 funds tracked by Wall St. Rank hold PACB as of Q3 2024.

  • Byrne Asset Management reported no remaining Pacific Biosciences position as of Q3 2024 after selling out during the quarter.
  • Byrne Asset Management sold 14,000 Pacific Biosciences shares in Q3 2024, an estimated $19K.
  • Byrne Asset Management first reported a position in Pacific Biosciences in Q2 2022 and held it in 4 quarters.
  • Byrne Asset Management's Pacific Biosciences position peaked at $30K in Q3 2022.
  • 226 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2024.

Based on Byrne Asset Management's 13F filing for Q3 2024, filed 28 Jan 2025.